Y Yuhong Li, MD

mFOLFIRINOX as Adjuvent Chemotherapy in Treating Chinese Pancreatic Cancer Patients

Although FOLFIRINOX regimen was recently presented to be effective as adjuvant chemotherapy for resectable pancreatic cancer in selected patients who have good physical condition, there is still insufficient evidence on this regimen in treating resectable pancreatic cancer patients in China. Since for many tumors, different races may show different responses …

M Meng zhang, MD

TCR-T Cell Therapy on Advanced Solid Tumors

The primary aim of this study is to evaluate the efficacy of KRAS mutant antigen specific TCR-T cells in the treatment of patients with advanced solid tumors. The secondary aim is to evaluate the pharmacokinetic/pharmacodynamic characteristics of TCR-T cell therapy in patients with advanced solid tumors and the survival of …

M Medical College of Wisconsin Cancer Center Clinical Trials Office

Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial

This is an open-label, phase II study in patients with resectable and borderline resectable pancreas cancer.

J Jiang Long, MD

Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver Metastasis

Clinical evaluation of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies. Construction of a combined treatment system of multimodal ablation therapy combined with immunotherapy and chemotherapy. Transformation and clinical application of multimodal ablation system for pancreatic cancer with hepatic metastatic malignancies.

W Weijing Zhang

PD-1 Combined With Chemotherapy and PULSAR in LAPC and Local Recurrence Patients

This trial is a phase II clinical trial of the safety and efficacy of PD-1 antibody (Toripalimab) in combination with paclitaxel (albumin-bound type) and gemcitabine and PULSAR radiotherapy in patients with locally advanced unresectable pancreatic cancer and patients with only local recurrence after pancreatic cancer surgery, to observe the safety …

T Toni Basinski, MS

Evaluating Obesity-Mediated Mechanisms of Pancreatic Carcinogenesis in Minority Populations

This study will evaluate obesity-mediated mechanisms of pancreatic carcinogenesis in minority populations.

G Gobind Gill, MD

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach

This trial is a single-arm, prospective, multi-center clinical trial designed to demonstrate that stereotactic adaptive radiotherapy using an ablatively dosed (50Gy,5fx) for treatment of borderline-resectable, locally-advanced , or medically inoperable pancreatic adenocarcinoma will translate into a decreased toxicity. The study will evaluate GI toxicity, overall survival, local control, quality of …

J Jean-Pierre BLEUSE, MD

Prospective Monocentric Clinical-biological Database

Pancreatic adenocarcinoma (PA) is a solid cancer with a very poor prognosis with overall survival, all stages combined, not exceeding 5% at 5 years. The incidence and number of deaths caused by this type of tumor have been steadily increasing for two decades. In the absence of therapeutic advances, PA …

C Chunmei Bai, M.D.

The Value of Molecular Residual Disease Monitoring Based on ctDNA in Resected Pancreatic Cancer

The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in resected pancreatic cancer. The main questions it aims to answer are: prognostic value of baseline MRD; the role of MRD dynamic changes after treatment in guiding treatment. Peripheral blood …

M Medical College of Wisconsin Cancer Center Clinical Trials Office

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma

Patients are randomized into two arms. Arm A patients will receive Stereotactic Body Radiation Therapy (SBRT) and Arm B patients with receive conventional concurrent chemotherapy and radiation therapy.